Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Endourology(Electronic Edition) ›› 2021, Vol. 15 ›› Issue (06): 463-466. doi: 10.3877/cma.j.issn.1674-3253.2021.06.003

• Clinical Research • Previous Articles     Next Articles

A pilot study on urinary PCA3 combined with multiparametric MRI for the diagnosis of prostate cancer

Ke Zhang1, Wei Jiang1, Zhuojun Li1, Weibin Mao1, Yue Zhang1, Zhan'ao Meng1,()   

  1. 1. Department of Radiology, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China
  • Received:2021-08-30 Online:2021-12-01 Published:2022-04-27
  • Contact: Zhan'ao Meng

Abstract:

Objective

To investigate the diagnostic value of urinary prostate cancer gene 3 (PCA3) combined with multiparametric MRI (mpMRI) in prostate cancer.

Methods

RT-PCR was used to detect the expression level of urinary PCA3 of 40 patients with prostate cancer and 28 patients with benign prostatic hyperplasia. The receiver operating characteristic (ROC) curves was constructed to analyze the sensitivity and specificity of urinary PCA3, mpMRI and the combination of them for the diagnosis of prostate cancer.

Results

The expression level of urinary PCA3 in benign prostatic hyperplasia was lower than that in prostate cancer [(2.26±0.95) copies/ml vs (6.25±1.21) copies/ml, P<0.001]. The area under ROC for PCA3, mpMRI, and the combination were 0.693 (95%CI: 0.569-0.799), 0.720 (95%CI: 0.598-0.822), and 0.830 (95%CI: 0.719-0.910), respectively.

Conclusions

The determination of urinary PCA3 combined with mpMRI was valuable biomarker for the diagnosis of prostate cancer.

Key words: Prostate cancer, Diagnosis, prostate cancer gene 3, multiparametric MRI

京ICP 备07035254号-20
Copyright © Chinese Journal of Endourology(Electronic Edition), All Rights Reserved.
Tel: 020-85252990 E-mail: chinendourology@126.com
Powered by Beijing Magtech Co. Ltd